Lowering blood pressure with renal denervation has been demonstrated in previous studies but unfortunately there was not much data regarding the reduction of clinical events. This study will enroll patients between 40 and 55 years of age with resistant hypertension plus risk factors for major cardiovascular events. A five year follow-up has been planned. The primary endpoint will be a composite of death, myocardial infarction, stroke or hospitalization for heart failure. For the study to have the statistical power to demonstrate a 25% reduction in the occurrence of events, it is necessary to recruit 4,000 patients.
Felix Mahfoud, MD
2013-05-21
Original title: EnligHTN: primary cardiovascular outcome safter renal denervation for resistant hypertension.